ATS Corporation (ATS) Q3 2026 earnings review
Strong Execution and Deleveraging Offset by Booking Softness
ATS delivered a robust operational quarter with 16.7% revenue growth (12.6% organic) and a 361% surge in Net Income. The diversification strategy is working: explosive growth in Energy (+161%) and Consumer Products (+57%) completely masked the collapse in Transportation (-22%). Crucially, the company executed on its deleveraging promise, bringing Net Debt/EBITDA down to 3.0x from 3.4x sequentially. However, the narrative is marred by a 10.4% decline in organic Order Bookings, signaling potential future deceleration despite a healthy 1.06x book-to-bill ratio.
🐂 Bull Case
The Energy segment is exploding, up 161% YoY to $72.2M. With a backlog of $296M (nearly doubled YoY), ATS is capitalizing on nuclear refurbishment and fuel fabrication demand. This high-value work is offsetting EV weakness.
Management successfully reduced the leverage ratio to 3.0x (from 3.9x at FY25 year-end). Strong operating cash flow ($114.6M) and working capital improvements (down to 16.4% of sales) are restoring balance sheet flexibility.
🐻 Bear Case
Total bookings fell 7%, but organic bookings dropped 10.4%. While lapping a tough comp, the trend indicates slowing momentum. The Life Sciences backlog—the company's core stabilizer—shrank sequentially from $1.14B to $1.09B.
Transportation revenue fell 22% YoY and backlog is down 43% YoY ($143M vs $250M). The EV sector remains a significant headwind, shrinking to a minor portion of the portfolio but dragging overall organic growth metrics.
⚖️ Verdict: 🟢
Solid. The operational execution is excellent, evidenced by margin stability and cash generation. The drop in bookings is a concern to watch, but the 1.06x book-to-bill suggests the sky isn't falling. The portfolio shift toward Nuclear and Consumer Products is proving timely.
Key Themes
Nuclear Energy: A New Pillar
Accelerating. Energy revenue surged 161% YoY. This is not a blip; backlog in Energy is up 87% YoY to $296M. The mix has shifted decisively toward nuclear refurbishment and fuel fabrication, providing long-cycle, high-value revenue that buffers the cyclicality of other segments.
Order Bookings Deceleration
Decelerating. Organic order bookings fell 10.4% YoY. While management cites high comps from 'large enterprise orders' in Life Sciences last year, the sequential trend is flat to down in key areas. Life Sciences backlog dropped $130M YoY ($1.22B to $1.09B), suggesting the 'lumpiness' is currently working against them.
Consumer Products Breakout
Accelerating. Consumer Products revenue jumped 57% YoY to $134M. This was driven by organic growth in warehouse packaging automation (Paxiom integration impact and organic synergy). Backlog is up 78% YoY ($321M vs $180M), indicating this segment is becoming a primary growth engine alongside Energy.
Balance Sheet Restoration
Accelerating. Net Debt to Adj. EBITDA improved to 3.0x from 3.9x at the start of the fiscal year. This was driven by the EV settlement collection earlier in the year and strong Q3 operating cash flow ($114.6M). Management expects to operate within the targeted 2.0x-3.0x range for the balance of the fiscal year, unlocking future M&A capacity.
Life Sciences Stagnation
Decelerating. Revenue grew only 3.9% (mostly FX), and bookings decreased compared to the prior year. Given this is the largest segment ($390M revenue), the lack of organic growth is a drag. Management cites 'timing of customer capital investment cycles' and high comps, but the backlog contraction (-10% YoY) warrants monitoring.
Margin Resilience amidst Mix Shift
Stable. Adjusted EBITDA margin expanded to 13.8% from 13.4% YoY. Despite the drop in high-margin Life Sciences backlog, the company maintained profitability, likely aided by the shedding of low-margin Transportation work and operational efficiencies (ABM). Gross margin dropped slightly (29.6% vs 30.4%), offset by SG&A leverage.
Other KPIs
Accelerating. Up from -1.2% in Q1 and +12.6% in Q2. Shows that despite the Transportation drag, the core portfolio is executing well.
Improving. Down significantly from 30.3% a year ago (impacted by EV settlement issues) and 18.3% in Q2. Getting closer to the long-term target of <15%.
Reversing. Massive turnaround from -$62.6M outflow in the prior year period. Driven by EV settlement collections and improved working capital management.
Guidance
Decelerating. Midpoint ($730M) implies a sequential decrease from Q3's $760M and slight growth vs prior year Q4 ($721M adj / $574M reported). This reflects the lower bookings intake from previous quarters filtering through to revenue.
Stable. Management expects to operate within this target range for the balance of the fiscal year, confirming the deleveraging cycle is largely complete.
Key Questions
Life Sciences Backlog Erosion
Life Sciences backlog dropped over $100M year-over-year. Is this purely timing of large enterprise orders, or are you seeing a structural pause in GLP-1 or Radiopharma CAPEX?
Energy Segment Sustainability
Energy revenue grew 161%. How much of this is lump-sum nuclear refurbishment revenue vs. recurring work? What is the normalized growth rate for this segment in FY27?
Consumer Products Margins
With Consumer Products becoming a major revenue driver (+57%), how does its margin profile compare to the corporate average? Is this mix shift dilutive or accretive to EBITDA margins?
Tariff Exposure
Management mentioned monitoring tariffs. What is the specific exposure of the Canadian manufacturing base to potential US tariffs on industrial machinery?